G9761 – Patients who use hospice services any time during the measurement period

Long description

Patients who use hospice services any time during the measurement period

Short description

Pt w/hosp anytime msmt per

Pricing indicator

00 Not separately priced by Part B (bundled, not covered or Part A only)

Medicare coverage

C Carrier judgment – coverage decided by the Medicare contractor

BETOS category

Z2 Undefined codes

Added

January 1, 2017

Last change

January 1, 2017 – No change

Nearby G codes

• G9753 – Documentation of medical reason for not conducting a search for dicom format images for prior patient ct imaging studies completed at non-affiliated external healthcare facilities or entities within the past 12 months that are available through a secure, authorized, media-free, shared archive (e.g., trauma, acute myocardial infarction, stroke, aortic aneurysm where time is of the essence)
• G9754 – A finding of an incidental pulmonary nodule
• G9755 – Documentation of medical reason(s) for not including a recommended interval and modality for follow-up or for no follow-up, and source of recommendations (e.g., patients with unexplained fever, immunocompromised patients who are at risk for infection)
• G9756 – Surgical procedures that included the use of silicone oil
• G9757 – Surgical procedures that included the use of silicone oil
• G9758 – Patient in hospice at any time during the measurement period
• G9759 – History of preoperative posterior capsule rupture
• G9760 – Patients who use hospice services any time during the measurement period
• G9762 – Patient had at least two hpv vaccines (with at least 146 days between the two) or three hpv vaccines on or between the patient's 9th and 13th birthdays
• G9763 – Patient did not have at least two hpv vaccines (with at least 146 days between the two) or three hpv vaccines on or between the patient's 9th and 13th birthdays
• G9764 – Patient has been treated with a systemic medication for psoriasis vulgaris
• G9765 – Documentation that the patient declined change in medication or alternative therapies were unavailable, has documented contraindications, or has not been treated with a systemic medication for at least six consecutive months (e.g., experienced adverse effects or lack of efficacy with all other therapy options) in order to achieve better disease control as measured by pga, bsa, pasi, or dlqi
• G9766 – Patients who are transferred from one institution to another with a known diagnosis of cva for endovascular stroke treatment
• G9767 – Hospitalized patients with newly diagnosed cva considered for endovascular stroke treatment
• G9768 – Patients who utilize hospice services any time during the measurement period
• G9769 – Patient had a bone mineral density test in the past two years or received osteoporosis medication or therapy in the past 12 months